Thinking on Improving and Guaranteeing the Quality of Traditional Chinese Medicine Preparations in Medical Institutions

Abstract

Abstract: Objective To improve and guarantee the quality of traditional Chinese medicine in medical institutions, protect and support the pharmaceutical preparations of medical institutions, and promote the development of traditional Chinese medicine in China.Methods Through establishing a market leverage price system that the quality classification system of Chinese herbal medicine and herbal decoction pieces matches with the market price lever of traditional Chinese medicine in medical institutions, strengthening the detectability construction of medical institutions' drug quality control rooms, establishing the regional center of preparation room, setting up traditional Chinese medicine quality risk detection platform for medical institutions, speeding up research on the standardization of traditional Chinese medicine preparations in medical institutions and improving the standardization research on Chinese medicine preparation method to promote the construction of quality assurance.Results We have formed a mechanism for improving and guaranteeing the quality of the traditional Chinese medicine preparations.Conclusion Traditional Chinese medicine preparations in medical institutions is an important part of Chinese medicine clinic, in view of the quality of traditional Chinese medicine preparations in medical institutions, take effective measures to improve the quality, ensure the safety and effectiveness of traditional Chinese medicine preparations for clinical use.

Key words: medical institutions, traditional Chinese medicine preparations, quality

CLC Number:

R954

SHI Bing-juan. Thinking on Improving and Guaranteeing the Quality of Traditional Chinese Medicine Preparations in Medical Institutions[J]. Chinese Journal of Pharmacovigilance, 2018, 15(5): 276-279.

References

[1] 仇宏,陈霞.当前医院制剂室发展的探讨[J].中国现代药物应用,2008,2(10) :106-107.
[2] 吴晓春,史颖.对当前医院制剂面临现状及发展方向的调查与思考[J] .中国现代医药杂志,2008,10(4):141-142.
[3] 李姝梅,宾婕,张家旭.关于医院制剂室现状及发展的几点思考[J].中国科技从横,2016, 250(22):192-193.
[4] CFDA.《中华人民共和国药品管理法》[EB/OL]. (2015-04-24)[2017-09-20]. http://www.sda.gov.cn/WS01/CL0784/124980.html.
[5] CFDA.《医疗机构制剂配置监督管理办法》（试行）（局令第18号）[EB/OL]. (2005-04-14)[2017-09-20]. http://www.sda.gov.cn/WS01/CL0053/24515.html.
[6] 林伟萍,刘丽仙,吴明东.对我国医院制剂存在与发展的思考[J].中国药业,2007,16(2):51-51.
[7] 陈鸣,林伊梅,马亮英.医疗机构制剂的作用及其管理[J].中国药事,2004,18(2):73-75.
[8] 中药商品知识编写组.《中药商品知识》中册[M].广东:广东科技出版社,1989:159.
[9] 山东省物价局.关于印发《山东省医疗机构制剂价格暂行管理办法》的通知（鲁价格发[2011]187号）[EB/OL]. (2011-11-14)[2017-09-20]. http://www.sdwj.gov.cn/ggfw/jggl/czc/11/36106.shtml.
[10] 北京市发展和改革委员会.《北京市医疗机构制剂价格管理办法》（试行）的通知（京发改[2008]1354号）[EB/OL]. (2008-09-22)[2017-09-20]. http://www.bjpc.gov.cn/zwxx/zcfg/xcwj/zcwj/201511/t9770255.htm.
[11] 河北省物价局.河北省物价局关于印发《河北省医疗机构制剂价格管理办法》的通知[EB/OL].(2013-12-11)[2017-09-20].http://www.hebwj.gov.cn/News.aspx?sole=20141225161259784.
[12] 王慧敏.医院制剂室的现状分析及发展策略[J].临床合理用药杂志,2011,4(14):158-159.
[13] 国家药典委员会.中国药典（一部）[S].北京:中国医药科技出版社,2015:133.
[14] CFDA.国家食品药品监督管理总局办公厅征求《关于开展药品生产工艺核对工作的公告（征求意见稿）》的意见[EB/OL].(2016-08-11)[2017-09-20]. http//www.scda.gov.cn/WS01/CL0788/162641.html.

[1]	FANG Zhie, LI Chengxian, BAI Zhaofang, ZHAO Xu, WANG Jiabo, XIAO Xiaohe. Investigation of objectivity in the relationship between aristolochic acid and hepatocellular carcinoma [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 20-24.
[2]	ZHANG Yuqi, XU Xinyi, ZHU Lan, ZHU Yan. Comparison standard terminology for pharmaceutical dose forms [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 904-910.
[3]	WANG Zhao, ZHAO Jianfeng, YU Xinlan, JIN Hongyu, MA Shuangcheng. Radiation screening of Chaihu Shugan pills via photostimulated luminescence [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 514-518.
[4]	MA Yun, HAN Zhenming, ZHANG Wei, MA Jian, GUAN Yongxia, ZHANG Guimin. Effects of ⁶⁰Co-γ ray irradiation sterilization on quality of Buthus martensii Karsch powder [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 519-523.
[5]	LI Ning, JIANG Xiaoya, ZHANG Zezhao, GAO Le, WANG Xinguo, LIU Xiaoming. Preparation and quality evaluation of standard decoctions of Rosa chinensis Jacq. [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 397-402.
[6]	LIU Jing, LIU Yan, ZHENG Xiaowei, WANG Qi, HE Fengyan, WANG Feifei, WANG Yadan, HE Yi, NIE Lixing, HU Xiaoru, DAI Zhong, MA Shuangcheng. Quality analysis of Guci tablets based on national drug evaluation sampling [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 292-295.
[7]	CAI Yuluo, GUO Jiahui, Wang Xinguo, TIAN Yilong, WANG Meng, NIU Liying, LI Junshan. Research progress in Yi medicine Valeriana jatamans and predictive analysis of related quality markers [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 348-352.
[8]	WANG Yadan, YAN Jiangong, CHEN Minghui, PANG Yu, DAI Zhong, MA Shuangcheng. UPLC fingerprints of tripterygium glycosides tablets from different manufacturers [J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 146-151.
[9]	WANG Guoying, ZHOU Gang, WANG Qin, JI Ziwei, NING Xiao, CUI Li. Analysis of impurity spectra and quality control of betahistine hydrochloride injection based on HPLC-QE-MS technology [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1332-1338.
[10]	HAO Gang, HAN Feng, ZHOU Gang, WU Xing, YAN Hao, LI Xuyang, HOU Hailing, NING Xiao, CUI Li. Methodological study of adenosylcobalamin bacterial endotoxin examination for injection [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1351-1356.
[11]	WANG Zhao, LIU Yue, ZAN Ke, LI Hailiang, JIN Hongyu, MA Shuangcheng. Preliminary study on extraction technology of tea extract used for Xinnaojian preparation [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1362-1367.
[12]	GUAN Haoyue, LIU Nian, QI Mengjie, SUN Baihao, LIU Xuejing, HU Yang, NIU Jianzhao. Quality analysis of donepezil hydrochloride tablet [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1375-1381.
[13]	TAN Liyuan, CAI Tong, WANG Yan. Research progress in quantitative analysis methods for chemical reference substances [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1209-1216.
[14]	LIU Kecheng, WEI Tanjun, CHEN Fei, XIAO Cheng, ZHANG Yinsu. Quality evaluation of Chaihu Shugan granules ria multi-component quantification combined with GRA and EW-TOPSIS method [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1243-1248.
[15]	LIU Bo, GUO Yunxiao, LIU Lisha, FAN Huihong. Research progress in key technologies for quality control of snake venom hemocoagulase drugs [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1195-1200.